Dear Reader,

I want to talk to you about Unilens Vision.

Back in July 2003, our Weiss Ratings system upgraded Unilens Vision (UVIC) to an urgent "Buy."

There was no buzz around it, no headlines and no analyst on CNBC talking it up. 

Over the next three months, the stock climbed 175%.
One year later, 12,753%.
And by the time our system finally issued a "Sell" on UVIC, the stock had gained 265,900%.

That's the same as turning a $10,000 position into a whopping $26 million.

Here's the most important thing to note here …

With access to our ratings, you didn't need to understand what Unilens Vision actually did or make any predictions to profit from it. You just needed to follow the signal.

That's the entire point of how our Weiss Ratings system is built — to remove the guesswork and emotion … and replace it with reliance on cold, hard data.

And the results speak for themselves.

In 22 consecutive years of "buy" signals, our system has not had a single losing year.

With an average gain of 305% across every single "buy" signal, including the stocks that didn't work out.

The best part? 

Right now, with the Middle East crisis still ongoing and the U.S. debt spiralling, our system has identified what it believes are the biggest "Buy" opportunities heading into the rest of 2026.

Companies most investors have never heard of, just like UVIC back in 2003.

I've recorded an urgent market broadcast where I walk you through exactly what our data is showing. And I'm giving away the names and ticker symbols of 3 stocks our system just upgraded to "Buy" completely free, right inside the video.

UVIC went up 265,900% before our system said "Sell." The investors who followed the signal didn't need to be experts. They just needed access to the right data. 

You can get that data with our ratings.

Click here to watch the broadcast and get your 3 free stock picks now.

Chris Graebe Weiss Ratings

Rocket Lab Is Back at a Line in the Sand—Now What?

Submitted by Ryan Hasson. Date Posted: 4/16/2026.

The space sector is having a standout year, and the momentum is building. The Procure Space ETF (NASDAQ: UFO), the most widely followed benchmark for the sector, is up more than 30% year to date, dramatically outpacing the S&P 500. Reports of a SpaceX IPO—with a potential valuation near $1.5 trillion—have injected fresh excitement and institutional capital into space stocks. A SpaceX listing would be one of the largest IPOs in history and could act as a rising tide for the entire sector.

At the center of that excitement is Rocket Lab (NASDAQ: RKLB). The company is often seen as the closest publicly traded competitor to SpaceX, offering launch services, spacecraft manufacturing, and a rapidly expanding portfolio of satellite components.

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla.

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.

👉 Unlock the ticker now and get it completely free.

Rocket Lab is one of the UFO ETF's top holdings and is up more than 200% in the past year. Now consolidating near key technical levels, the stock is drawing increasing attention from investors and traders alike.

The Technical Setup

From a technical analysis perspective, RKLB presents one of the more interesting setups in the sector. Although the stock has fallen roughly 27% from its 52-week high, its broader uptrend remains intact.

After previously breaking below multi-month support near $65, the stock has reclaimed that key level. It has also moved back above its key Simple Moving Averages (SMAs). As of Tuesday’s close, RKLB had reclaimed its 20- and 50-day SMAs while remaining above its 200-day SMA. If RKLB can reclaim $78 and hold above it, that would likely signal a higher-timeframe breakout and the start of a fresh leg higher.

It's Not Just the Chart: Rocket Lab Is Making Major Fundamental Strides

What makes the current setup particularly compelling is that the technical picture is being supported by meaningful fundamental progress. On April 14, Rocket Lab announced two significant developments that underscore the company's accelerating vertical integration strategy.

First, the company completed the acquisition of Mynaric, paying aggregate consideration of $155.3 million through a nominal cash payment and roughly 2.28 million shares of common stock. The deal adds laser optical communications terminals to Rocket Lab's growing portfolio of satellite components, establishes the company's first European footprint, and deepens its ability to serve both commercial constellation operators and national security customers. It's a meaningful step in Rocket Lab's evolution from a launch provider into a more fully integrated space systems company.

Second, Rocket Lab introduced Gauss, a new electric satellite thruster designed for high-volume production. Electric propulsion has historically been one of the most persistent supply-chain bottlenecks in the satellite industry; producing these thrusters at scale has proven difficult, creating reliability challenges for constellation operators. Rocket Lab has already established a production line capable of manufacturing more than 200 Gauss thrusters per year, directly addressing that bottleneck.

The Gauss thruster integrates a Hall thruster, a power processing unit, and a propellant management assembly. It delivers higher specific impulse than traditional chemical propulsion systems, making it more fuel-efficient and better suited for long-duration missions and satellite station-keeping. As CEO Sir Peter Beck said, proliferated constellations are now the norm, but the propulsion systems needed to maneuver those spacecraft haven't been reliably available at scale.

Together, the Mynaric acquisition and the Gauss announcement show a company systematically identifying and solving supply-chain constraints in the space industry at scale. This is the same playbook that has driven Rocket Lab's broader success: identify critical components that aren't available in volume, build or acquire the capability to produce them, and embed those capabilities into its own satellite programs and customer contracts.

Analysts Continue to Pound the Table on RKLB

Analysts maintain a consensus Moderate Buy rating on RKLB based on 17 analyst ratings, with a consensus price target of $79.85—implying just over 10% upside from current levels. That sentiment has grown more bullish recently: on April 14, Citigroup upgraded the stock from Market Perform to Outperform.

With speculation around a SpaceX IPO adding sector-wide momentum, the Mynaric acquisition closed, and the Gauss thruster addressing a genuine industry bottleneck, Rocket Lab is entering one of its most catalyst- and momentum-rich periods.

These 3 Psychedelic Stocks Activated After Trump's Executive Order

Submitted by Nathan Reiff. Date Posted: 4/27/2026.

The Trump administration's April 2026 executive order supporting psychedelic drugs may have flown under the radar for many investors amid the conflict in Iran and other high-profile domestic political stories. The implications for this small but growing industry, however, are significant. Within days the FDA began to act, awarding priority review vouchers to select companies developing drugs in this category and thereby potentially shortening review times considerably.

Single-session wins were to be expected for some of the larger players in the psychedelics industry, and share prices for several companies rose sharply. Over the longer term it will be up to these developers to demonstrate that their medicines can deliver results. Here are a few companies worth watching.

A Promising Candidate Could Reach Market Sooner, Easing Financial Pressure

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla.

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.

👉 Unlock the ticker now and get it completely free.

One of the biggest beneficiaries of the executive order was biotech firm Compass Pathways (NASDAQ: CMPS), whose shares surged by nearly 80% in the past month. The enthusiasm centers on COMP360, a drug candidate for treatment-resistant depression that received a priority voucher.

Compass has struggled to maintain operational viability while advancing a drug that many view as promising. The company has reported mounting net losses in recent years, and its weighted-average basic shares outstanding have more than doubled over that period, widening losses per share.

A shorter runway to commercialization for COMP360 could materially improve Compass's financial outlook. The stock was already rated a Buy by several analysts, and it received a fresh wave of bullish ratings and higher price targets after the executive order. As of late April, eight of 10 analyst ratings were Buys, and the consensus implies more than 100% upside, even after the recent rally.

Another Speculative Penny Stock With a Promising Candidate

Clinical-stage biotech AtaiBeckley (NASDAQ: ATAI) also saw a mid-April surge after reporting positive results from an earlier phase of BPL-003. Phase 3 trials for BPL-003 aren't scheduled to begin until later in 2026.

With current sales of roughly $4 million annually, AtaiBeckley carries a very high price-to-sales (P/S) ratio in the 400s, a sign that the stock is valued far above its present revenue. The firm is pre-profit and trades as a penny stock, with shares below $5 even after the recent boost. That makes ATAI a speculative, potentially volatile investment.

Still, broader momentum behind psychedelic treatments for mental health could accelerate BPL-003's path to market. Ten of 12 Wall Street analysts rate the stock positively, and the consensus price target of $14.63 implies more than 200% upside, considerably higher than Compass's implied upside.

A Potential Generalized Anxiety Disorder Treatment With Strong Analyst Backing

Definium Therapeutics Inc. (NASDAQ: DFTX), previously known as Mind Medicine, has also posted significant net losses in recent years. However, it ended 2025 with $258 million in cash and equivalents, which gives it runway to advance MM120, a drug candidate for generalized anxiety disorder.

Like the other candidates mentioned, MM120 targets a very large addressable market. Successfully commercializing it could move Definium from a speculative play toward a much larger biopharma opportunity.

DFTX shares have risen roughly 25% in the past month on the news, and analysts are generally bullish. The stock has 14 Buy ratings and only one Sell, with forecasts implying about 70% upside potential.

If individual names feel too risky, investors can gain diversified exposure to the space through a niche exchange-traded fund such as the AdvisorShares Psychedelics ETF (NYSEARCA: PSIL). The fund is actively managed (it carries a relatively high expense ratio of 1%), but it provides access to roughly two dozen companies in the sector—helping investors benefit from any single firm's breakthrough while reducing company-specific risk. PSIL also currently offers a dividend yield of about 8.5%, which may appeal to income-oriented investors.